Podcasts about xiidra

After getting her first pair of glasses at age 12 and seeing the individual leaves on trees for the first time, Pam knew she'd be an optometrist. As an adult, she struggled with her own dry eyes, which led her to focus on helping others alleviate their symptoms. Today, Dr. Pam Theriot advocates for 4 simple steps for a daily hygiene routine: Hydrate, Harmonize, Heat, Heal. Listen in to hear how Dr. Theriot is sharing her knowledge with the masses through her clinic, her book and now the metaverse: https://theomniverse.city/dry-eye-metaverse/Learn more about Dr. Pam TheriotFind her book "Alleviate Dry Eye"  Key Moments 0:48 Dr. Allen introduces Dr. Pam Theriot 2:05 How Dr. Theriot found optometry 3:17 Moving around as a military spouse 5:38 Creating a dry eye clinic 8:43 The path to self-publishing 13:48 Preparing patients prior to initial consultation 14:40 post-appointment follow-up communication 16:43 Dr. Theriot's 4 simple steps for daily eye hygiene 18:11 Recommending nutritional supplements with Omega fatty acids 20:57 Dry eye technology and treatments 23:03 The future dry eye treatments 25:48 The first dry eye clinic in the Metaverse 33:07 Eye care should be part of your daily health care Eye Give a Damn hosted by Dr. Joseph Allen is produced by FluoreSCENE Media.For more information on Dr. Joseph Allen visit https://doctoreyehealth.com/Visit https://odcommunity.com/ to learn more about FluoreSCENE Media.

I am not a medical professional, etc. I am simply sharing what has helped relieve my severe dry eyes.

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company is seeing record numbers as they release its 3rd quarter financial numbers. Saviuk told Proactive the company saw record revenues of 6.1 million in Q3 which was a 27% increase over Q2-22. Grose Margins also set a news record with a 34% increase over Q2. Saviuk is also projecting Q4 revenues to exceed $11 million dollars led by products XIIDRA, SIMBRINZA and ALLERJECT. Saviuk also shared with Proactive the company has entered into a deal to commerlize the drug Sabizabulin for COVID-19. Sabizabulin is an antiviral targeted for the treatment of hospitalized moderate-severe COVID-19 patients. #proactiveinvestors #valeopharma #biotech #tsxv #otcqb

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has completed a non-dilutive 40 million dollar Secured Term Loan with Sagard Healthcare Partners. Saviuk telling Proactive that financing will now allow the company to support three new drugs that will transform the company. Saviuk said the company will have the Canadian license Xiidra and Simbrinza from Novartis Pharmaceuticals Canada, which are in the field of Ophthalmology and dry eyes. The money will also be used to for the acquisition of the Canadian license rights to Allerject from Kaleo which is a auto-injector for the treatment of serious allergic reactions.

TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B). The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.

Today I'm answering listener questions. Jonathan sent me this question recently: "I was diagnosed with inherited AMBB (Anterior Basement Membrane Dystrophy) and dry eye. I know what to do to try to treat the dry eye and general inflammation, but I was interested in any alternative approaches to AMBB, especially any opinions about what may cause it other than “genetics”. My doctor is having me do Muro and Xiidra and outlined a series of progressive treatments. I wonder if serious fasting to trigger autophagy might help rebuild the cornea instead of a resurfacing procedure if it comes to that. I am also using Avenova or equivalent and various dry eye drops, as well as hot compresses and omega-3s. But I think my main problem is air conditioning, dry climate, and excessive screen time for work and entertainment.  What do you recommend?” So let's dive in. Enjoy the show! If you want more, sign up for my newsletter at: www.drsamberne.com and if you have questions, you can send them to hello@drsamberene.com. SUMMARY KEYWORDS cornea, corneal, eye, eyelids, inflammation, MSM, health, dystrophy, eyedrops, collagen, tears, diagnosed, systemic, dry, natural, lymphatic, support, helpful, imbalance Hello, everyone, it's Dr. Sam, I'd like to welcome you to my EyeClarity podcast. This is a show that offers cutting-edge information on how to improve your vision and overall wellness through holistic methods. I so appreciate you spending part of your day with me. If you have questions, you can send them to hello@drsamberene.com. Now to the latest EyeClarity episode. Hey folks, it's Dr. Sam and I want to welcome you to another AI clarity podcast. Today we have a very interesting question from a gentleman, and it has to do with his cornea. But before we get to that, I want to announce my upcoming course on how to reverse cataract. This is an opportunity for you if you've been diagnosed with cataracts, to learn holistic methods to improve lens health, and possibly avoid surgery. I'll be offering some of my techniques that I've developed over three decades, things like physical life therapy, nutrition tips, energy, medicine, and many other things. So if you would like to sign up, go to my website, Dr. Sam Berne calm. I'm also on Facebook and Instagram, or you can send me an email Hello at Dr. Sam berne.com. So I'm going to take this question today from Jonathan. And he says that he has he has been diagnosed with an inherited, it's called anterior basement membrane dystrophy. And he's also been diagnosed with dry eye. And he says in his email to me, I know what to do to try to treat the dry eye in general inflammation. But I was interested in any alternate approaches to this corneal dystrophy which he calls a MBB. And he wants to know if it's caused by genetics, or are there other reasons why we might develop corneal dystrophies right now he's using muro, eyedrops and xiidra. eyedrops, and he's not really getting much of a change. He's also using avid Nova which probably helps reduce the dry eye. He's also using hot compresses and omega threes. He says his main problem is air conditioning, dry climate and excessive screen time for work and entertainment. Alright, Jonathan, fasten your seat belts. So first of all, when we talk about this particular condition called interior basement membrane dystrophy. This is also can be known as map dot fingerprint, corneal dystrophy Coogan's microcystic dystrophy. And it is an inherited disorder that affects the corneal surface and it can create a erosions blurred vision distorted vision. And what happens with these certain corneal erosions is they tend to reoccur, especially when you wake up in the morning, you know, the driest part of your eyes usually occur between when you go to bed at night and when you wake up in the morning, and it is probably the most common corneal dystrophy. You know, I've read studies were two to 3% of the entire population has been diagnosed with this corneal dys...

I discuss my journey with chronic dry eye. Products discussed: Flaxseed Oil and Rohto Eye Drops. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

In this episode Dr. Suh interviews Dr. Ken Beckman about all aspects of dry eye disease. They first delve into the common signs and symptoms. Dr. Beckman then discusses the special tests that can be performed at your eye doctor’s office to confirm which type of dry eye disease you may have. Lastly, he does a comprehensive review of the wide-ranging treatments that are available today. Below are links to some more information about topics that are discussed on this episode.Tear osmolarity measures the salt concentration of human tears to aid in the diagnosis of dry eye disease.InflammaDry detects high levels of MMP-9, an inflammatory marker that is consistently elevated in the tears of patients with chronic dry eyes.Lipiscan is a high-definition oil gland imager that allows eye care professionals to assess meibomian gland structureThis is one of the brands of moist heat eye compresses that Dr. Beckman recommends in his office to help patients with evaporative dry eyes – the most common cause of dry eye disease. Lipiflow is a procedure performed in the office that heats and massages the eyelids to improve outflow of the natural oil from the glands that are so vital for a stable tear film layer.This is a nice summary article about the three prescription dry eye medications – cyclosporine-A (Cequa and Restasis) and lifitegrast (Xiidra).Punctal plugs, a quick, in-office procedure covered by insurance, are a nice adjunct to combat dry eyes. Autologous serum drops are eye drops made from a patient’s own blood plasma and serum. Scleral contact lenses can be worn to treat severe dry eyes. This is an old article but still relevant.This is a nice summary article on dry eyes from the American Academy of Ophthalmology Dr. Beckman was one of the lead authors in this landmark, peer-reviewed journal article that changed paradigms about dry eyes.You can find out more about Dr. Beckman and Suh's practice at their website and on Facebook.This is intended for informational and educational purposes only, and nothing in this podcast/blog is to be considered as recommending or rendering medical advice or treatment to a specific patient. Please consult your eye care specialist for proper diagnosis and treatment of any eye conditions that you may have.

Patrick Mooney, head of Novartis’ US eye care business, lays out Novartis’ plans following the spin-out of Alcon and bid to acquire the former Shire ophthalmology franchise from Takeda. Where does Novartis see future growth in eye care? Will ophthalmologists and optometrists see a difference? Is Novartis done acquiring products for a while?

In Episode 5, Darrell White, MD, shares his thoughts on why every ophthalmologist in every subspecialty should be aware of the prevalence of dry eye and its impact on eye care. Everyone – including retina specialists need to be aware of dry eye :58 Financial disclosures 1:10 The hot dot in eye care 1:40 The space is growing: More people have dry eye and it’s affecting more of their lives 2:31 Dry eye and presbyopia-correcting IOLs 3:17 White’s personal dry eye story 4:54 Starting a dry eye practice from scratch 7:37 The archetypal patient defined in market research done by Allergan 8:12 The 3-generation decision maker on medical care for the family 9:10 Going from 0 patients on day 1, to more than 5,000 active patients in the first year 11:08 What has changed since then 11:52 Multi-screen lifestyle increasing dry eye population 12:05 The biggest symptom is blurry vision 13:34 The Linda Blair dry eye patient 14:41 Listen to your patient 15:56 Treating meibomian gland disease Diagnosing dry eye 17:50 Treating the dry eye patient 18:51 Artificial tears 19:00 Hypotonic tears 19:30 Restasis and Xiidra 20:56

In interviews at OIS@AAO, we talk with Robert Dempsey, global head of Shire’s ophthalmic business, about the international launch of Xiidra. Joseph Boorady, CEO and president of TearScience, lays out the company’s plans since being acquired by Johnson & Johnson Vision. Finally, Tom Gadek, president and CEO of TearSolutions, explains how he’s hoping to score another winning dry eye treatment with a start-up.

Charles Semba, MD, is one of the more recognized and accomplished figures in development of new ophthalmology treatments. He has played integral roles in the development of Lucentis, Xiidra, and more recently Forsight IV’s drug delivery technology. Now the chief medical officer at Graybug Vision, Dr. Semba is working to develop a technology that could significantly reduce the number of injections needed to deliver drugs to the back and front of the eye. But how did Dr. Semba, who had been a world renowned vascular specialist, run out such a string of successes in ophthalmology? And what is the biggest regret of his accomplished career?

Now that Shire’s Xiidra claims a 20% market share, find out how it’s impacting the practice. Alice Epitropoulos, MD, of Ophthalmic Surgeons & Consultants of Ohio, sat down with OIS-TV to explain how Shire, TrueTear, and other advances are impacting her Dry Eye patients.

Three-year-old TearSolutions hopes to pen a strong sequel to SARCode’s successful tale of a start-up developing the next new treatment for Dry Eye Disease. Tom Gadek, co-founder of SARCode, developer of lifitegrast (now Shire’s potential blockbuster Xiidra), takes over the company as it begins courting partners and investors.

Shire scored a huge win this summer by securing FDA approval of Xiidra. Hear from three principals of SARcode Bioscience, the start-up that discovered the Dry Eye treatment – then known as lifitegrast.

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Shire CEO Flemming Ornskov on the outlook for the company after getting FDA approval for Xiidra drops to treat dry-eye disease.

Today in FirstWord:

Robert Dempsey joined Shire to build a new ophthalmology unit. Until now, the division had been mostly theoretical with no products to sell. Now, the brand building is over. Shire officially has entered the ophthalmology sector with the launch of its potential blockbuster, Xiidra. Hear what’s next for the Dry Eye treatment and what else we can expect to see from Shire’s pipeline.